You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid Point-of-Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood

    SBC: ZYMERON CORP            Topic: NIAID

    TuberculosisTBis currently the leading infectious cause of death worldwideTB treatment includes multiple different combinations of antibioticsdosesand long time periodsThe current standard includes an intensive phase ofmonthsfollowed by a continuation phase of eitherormonthsHowevertreatment outcome can be poor due to drug drug interactionsimpaired medication adherencedrug absorption and metabolism ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Mobile Health Point-of-Care Diagnostics for Tuberculosis

    SBC: B & W TEK INC            Topic: NIAID

    TuberculosisTBkilled an estimatedmillion people in the world inOverof the mortalities associated with this deisease occurred in regions of the world where access to reliable TB testing and other suppotive infrastructure is severely limitedUntil there are pivotal technological innovations in the diagnosis of TB for point of carePOCapplicationthe ambitious goals of the WHO s End TB strategyareductio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents

    SBC: ZYMERON CORP            Topic: NIAID

    HIV disease continues to be a serious health issue for the whole worldCurrentlyantiretroviral therapyARTis a widely accepted treatment to HIV infected patientswhich reduces morbidity and mortality and the potential for HIV transmission by suppressing viral replicationHowevertreatment outcomes of ART are limited due to the high adherence requirement and occurrence of drug resistanceProteolysis targ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: ZYMERON CORP            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. SBIR PHASE 1- TOPIC 394- COMBINATORY TREATMENT MODALITIES UTILIZING RADIATION TO LOCALLY ACTIVATE OR RELEASE SYSTEMICALLY DELIVERED THERAPEUTICS.

    SBC: ZYMERON CORP            Topic: NCI

    Photodynamic therapyPDTutilizes light beam to activate photosensitizers to produce cytotoxic reactive oxygen speciesROSand it has been proposed as a potent treatment to combine with Radiation TherapyRTespecially for the idea of using X ray beam to locally activate PDTXPDTMajority studies about XPDT have used nanoscintillators as the X ray transducer to activate photosensitizersHoweverthe materials ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW

    SBC: CELL MICROSYSTEMS INC            Topic: NCI

    Combining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Strong protections, tracking, diversion detection, and deactivation of opioid medications in the hospital and related caregiving settings.

    SBC: Curazel LLC            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop a comprehensive approach to allow hospitals gain control of their opioid medicationsThe Contractor approach is totrack opioids from the pharmacy to the patienttrack the amount given to the patientand for opioid waste to track it back to the pharmacybetter administer opioids to patients that offe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. An integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings.

    SBC: CERTIRX CORPORATION            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop an integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. DEVELOP NEW COMMERCIALLY VIABLE DEVICES, TOOLS, TECHNOLOGIES OR INTEGRATED SYSTEMS FOR DRUG DETECTION AND DEACTIVATION TO DETER OPIOID THEFT IN HOSPITALS.

    SBC: B & W TEK INC            Topic: NIDA

    The Contractorwill use modern technology to develop a fully integratedcommercially viable device for controlled pharmaceutical drug detectiondeactivationand disposal to ensure compliance with DEA regulations and deter opioid theft

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Improving Spatiotemporal Precision in Noninvasive Electrical Neuromodulation

    SBC: Brain Electrophysiology Laboratory Company, LLC            Topic: 101

    This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government